Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.
IL-23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subun...